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years PFS was 79% and 40%, respectively. Median time to 
progression and median OS were 18 months and 24 months, 
respectively. Local control was 93% at 1 year and 64% at 2 
years. Local progression occurred in 4 metastases (14%). 
Overall, acute toxicity occurred in 18% (4/22) of patients; 
two patients experienced grade 2 pneumonitis. Grade 1-2 
late toxicity occurred in 50% of patients. No grade≥3 
toxicities were recorded. 
Conclusions: Local treatment is a feasible and well-tolerated 
treatment for oligometastatic NSCLC patients. Ablative RT 
has a potential role in the local control of the lung 
metastases and in the management of well-selectedstage IV 
NSCLC patients in increasing quality of life and survival. 
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Purpose/Objective: The aim of this study was investigate 
whether the standardized uptake value (SUV-max) of tumor 
from [18F]-fluoro-2-deoxy-glucose positron emission 
tomography (FDG-PET) was associated with outcome in 
patients with non-small-cell lung cancer (NSCLC) treated with 
curative stereotactic body radiotherapy (SBRT). 
Materials and Methods: Between January 2006 and January 
2014, a total of 46 patients with medically inoperable early 
stage NSCLC underwent SBRT. 32/46 (69.57%) and 14/46 
(30.43%) had stage IA and IB, respectively. The treatment 
was administred as 40-50 Gy in 5 fractions; the dose was 
prescribed to the isocenter. Histology was confirmed in 36/46 
(78.26%) patients. All received FDG-PET/computed 
tomography (CT) at the same institution before SBRT, 3-4 
months after the end of SBRT and every 4-6 months 
thereafter. We reviewed the values of the metabolic activity 
of the lung lesion before and after treatment, expressed as 
maximum standardized uptake value (SUV-max) before SBRT 
(SUV-max pre-SBRT), first SUV after SBRT (1st SUV-post-SBRT) 
and the lowest value of SUV in the longitudinal follow-up 
(SUV-nadir). The values were then analyzed with Cox 
proportional hazards regression to assess whether the 
metabolic activity could has a predictive value in treatment 
outcome: local failure (LF), mediastinal failure (MF), 
systemic progression (SP), overall survival (OS) and cancer 
specific survival (CS). 
Results: Median follow-up was 20.5 months (range 4 – 91) for 
whole group. The median SUVmax pre-SBRT was 7.70 
(range,1.4-28.9), median 1st SUV post-SBRT was 3.25 (range 
0.0-9), median SUV-nadir was 1.90 (range 0.0-8). Local 
complete and partial response was observed in 37/46 
(80.43%) and 9/46 (19.57%) patients, respectively. Kaplan-
Meier three-years LF, MF, SP were 18.7%, 5% and 5%, 
respectively. Three-years OS and CS were 67.7% and 82.1%, 
respectively. We have found similar rates of response in 
terms of complete and partial response, even if the SUVmax 
before treatment was higher or lower than the median value 
in our study (7.70). In univariate analysis, SUVmax pre-SBRT, 
1st SUV-post-SBRT and SUV-nadir did not predict for LF, MF, 
SP, OS and CS.  
Conclusions: SBRT was an effective treatment for medically 
inoperable early-stage NSCLC. On the basis of our results PET 
SUV-max pre-SBRT, 1st SUV-post-SBRT and SUV-nadir did not 
predict for LF, MF, SP, OS and CS. 
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Purpose/Objective: A murine breast cancer xenograft model 
was employed to evaluate inter- and intra-variability of 
various parameters derived from dynamic positron emission 
tomography with [18F]fluorodeoxyglucose as tracer (FDG-
PET). 
Materials and Methods: 17 female athymic nude foxn1/nu 
mice with bila-terally implanted triple-negative basal-like 
ductal carcinoma (MAS98.12) breast cancer xenografts 
underwent a dynamic PET scan over an hour after injection 
of ~10 MBq FDG. Inter-animal data were obtained from the 
entire animal cohort, while intra-animal data were obtained 
fro-m four mice which received an additional scan after one 
or two days. Standardised uptake values (SUVmax, SUVmean and 
SUVmedian) were estimated for all tumours and livers at 
different time points. Tumour uptake was analysed with 
Patlak analysis and a full kinetic two-compartment model for 
estimation of pharmacokinetic parameters. The coefficient of 
variation (CV) was calculated for all PET-derived metrics. 
Results: The CV for SUVmean and SUVmedian was typically 10-20% 
for the tumours, depending on the time post injection and 
group (intra vs inter). The CV for SUVmax was mostly higher at 
all time points p.i. The variability in the pharmacokinetic 
parameters ranged from 23 to almost 150%. 
Conclusions: SUVmean and SUVmedian show less variability than 
SUVmax. Still, pharmacokinetic tumour metrics show much 
greater variability than the SUV based metrics. However, it is 
generally not known which of these metrics that best 
represents cancer aggressiveness and their use may still 
depend on the research questions addressed. 
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